Background II
The phase IIb HIV vaccine trial called STEP evaluating the protective effect of The phase IIb HIV vaccine trial called STEP evaluating the protective effect of MRKAd5 vaccine was prematurely stopped due to a lack of efficacy of the vaccine
Buchbinder et al, Lancet 2009
The RV-144 trial evaluating the protective effect of poxvirus-derived ALVAC-HIV in combination with a recombinant gp120 subunit vaccine prevented HIV i f ti (31 2% ffi ) infection (31.2% efficacy)
Rerks-Ngarm et al, NEJM 2009
None of the previous studies evaluated 1) the presence of pre-existing Adspecific or pox-specific T cells in gut mucosal tissues, which may impair HIVvaccination efficiency, and 2) the induction of HIV-specific T cells in gut mucosal tissues mucosal tissues 
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